It has been reported that EGCG treatment significantly improves cognitive deficits, amyloid precursor protein processing, and tau pathology in D-gal-induced AD mice, Tg2576 (APPswe), and PS2 transgenic mice [77,78]. The gene discussed is MAPT; the disease is Alzheimer disease.